newsfilter
← Latest News
GlobeNewswire·

Checkmate Pharmaceuticals Announces Second Quarter 2021 Financial Results and Provides Business Update

Clinical trial programs for vidutolimod (CMP-001) in melanoma and head and neck cancer indications ongoing Trial start-up activities to support non-melanoma skin cancer indications underway Multiple clinical data readouts anticipated in 2022 CAM